7-[(4-Benzoylpiperazin-1-yl)methyl]-3,12-dimethyl-2,9-dioxatetracyclo[9.3.0.01,3.06,10]tetradec-12-en-8-one

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: 7-[(4-Benzoylpiperazin-1-yl)methyl]-3,12-dimethyl-2,9-dioxatetracyclo[9.3.0.01,3.06,10]tetradec-12-en-8-one
• 化学式: C₂₆H₃₂N₂O₄
• 分子量: 436.5
• InChiKey: NSLRPAXRVGEKKC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  32
• 可旋转键数：
  3
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  62.4
• 氢给体数：
  0
• 氢受体数：
  5

文献信息

• Methods and compositions for modulating serum cortisol levels
  申请人：Lecanu Laurent

  公开号：US20060194815A1

  公开（公告）日：2006-08-31

  The present invention relates to cortisol-modulating compounds, including but not limited to benzamide and benzoic acid derivatives such as procaine and procaine derivatives, utilized in compositions and methods for treating cortisol-mediated disorders, including but not limited to age-related depression, hypertension, Alzheimer's disease, and acquired immunodeficiency syndrome.

  本发明涉及皮质醇调节化合物，包括但不限于苯甲酰胺和苯甲酸衍生物，如普鲁卡因和普鲁卡因衍生物，用于治疗皮质醇介导的疾病的组合物和方法，包括但不限于年龄相关性抑郁症，高血压，阿尔茨海默病和获得性免疫缺陷综合症。
• Benzamide compounds
  申请人：Papadopoulos Vassilios

  公开号：US20060194814A1

  公开（公告）日：2006-08-31

  The invention provides a therapeutic method for preventing or treating a pathological condition or symptom in a mammal, such as a human, wherein the infectivity of a pathogen such as a retrovirus toward mammalian cells is implicated and inhibition of its infectivity is desired comprising administering to a mammal in need of such therapy, an effective amount of an N-benzamide derivative of a piperazinyl amide of an amino acid thereof that inhibits pathogenic infectivity, including pharmaceutically acceptable salts thereof. The invention also provides a therapeutic method for preventing or treating a neuropathological condition or symptom in a mammal, such as human, comprising administering to a mammal in need of such therapy, an effective amount of an N-benzamide derivative of a piperazinyl amide of an amino acid thereof, including pharmaceutically acceptable salts thereof.

  本发明提供了一种治疗方法，用于预防或治疗哺乳动物（如人类）中的病理状况或症状，其中涉及病原体（如逆转录病毒）对哺乳动物细胞的感染性，并且希望抑制其感染性，包括向需要该疗法的哺乳动物施用有效量的N-苯甲酰基衍生物的哌嗪酰胺及其氨基酸，其抑制了病原体的感染性，包括其药物可接受的盐。本发明还提供了一种治疗方法，用于预防或治疗哺乳动物（如人类）中的神经病理状况或症状，包括向需要该疗法的哺乳动物施用有效量的N-苯甲酰基衍生物的哌嗪酰胺及其氨基酸，包括其药物可接受的盐。
• Use of (4-Alkylpiperazinyl)(phenyl) methanones in the treatment of alzheimer's disease
  申请人：Lecanu Laurent

  公开号：US20090197891A1

  公开（公告）日：2009-08-06

  The invention provides a therapeutic method for treating at least one symptom of Alzheimer's disease in a mammal, such as a human, wherein the toxicity of a pathogen of β amyloid peptide mammalian cells is implicated and inhibition of the subsequently-induced pathological pathways is desired comprising administering to a mammal in need of such therapy, an effective amount of a benzoylpiperazine derivative, including pharmaceutically acceptable salts thereof.

  本发明提供了一种治疗哺乳动物，如人类阿尔茨海默病至少一种症状的治疗方法，其中涉及β淀粉样肽哺乳动物细胞的病原体毒性，并且希望抑制随后诱导的病理途径，包括向需要此类治疗的哺乳动物施用有效量的苯甲酰哌嗪衍生物，包括其药学上可接受的盐。
• Neuroprotective benzoate and benzamide compounds
  申请人：Lecanu Laurent

  公开号：US20060167108A1

  公开（公告）日：2006-07-27

  The invention provides a therapeutic method for treating at least one symptom of a neurological disorder or disease such as Alzheimer's disease in a mammal, such as a human, wherein the toxicity of a pathogen of β amyloid peptide and/or glutamate in mammalian cells is implicated and inhibition of the subsequently-induced pathological pathways is desired comprising administering to a mammal in need of such therapy, an effective amount of an N-arylamide or an (N-aminoalkyl)benzamide, including pharmaceutically acceptable salts thereof.

  本发明提供了一种治疗方法，用于治疗哺乳动物（如人类）的神经紊乱或疾病（如阿尔茨海默病）的至少一种症状、其中牵涉到哺乳动物细胞中β淀粉样肽和/或谷氨酸的病原体的毒性，并希望抑制随后诱发的病理途径，包括向需要此类治疗的哺乳动物施用有效量的N-芳酰胺或（N-氨基烷基）苯甲酰胺，包括其药学上可接受的盐。
• NEUROPROTECTIVE BENZOATE AND BENZAMIDE COMPOUNDS
  申请人：Lecanu Laurent

  公开号：US20090286876A1

  公开（公告）日：2009-11-19

  The invention provides a therapeutic method for treating at least one symptom of a neurological disorder or disease such as Alzheimer's disease in a mammal, such as a human, wherein the toxicity of a pathogen of β amyloid peptide and/or glutamate in mammalian cells is implicated and inhibition of the subsequently-induced pathological pathways is desired comprising administering to a mammal in need of such therapy, an effective amount of an N-arylamide or an (N-aminoalkyl)benzamide, including pharmaceutically acceptable salts thereof.